RETA - חוב כולל להון Reata Pharma

The success of Reata Pharmaceuticals (RETA) relies on the promotion of Skyclarys for the treatment of Friedreich's ataxia and the penetration of niche markets, while this price chart shows that the total debt-to-equity ratio is 3.44. Human capital has been strengthened through the merger with Biogen, which eliminated the risk of losing expertise. The future of the business depends on the approval of insurance reimbursements and the results of the final testing stages for new drugs.

The selection of reliable issuers is based on an analysis of the liability structure, where the ratio of total liabilities to equity determines the business's resilience to external shocks. The current debt-to-equity ratio measures the degree of financial leverage, which, given the full capacity utilization of Reata Pharmaceuticals (RETA) in producing orphan drugs, confirms the company's ability to maintain operational stability without excessive borrowing.